Quick Answer
Entrada Therapeutics, Inc. reported Total Revenue of $25.42 million for the year ending 2025.
- Entrada Therapeutics, Inc. showed a decrease of -87.9% in Total Revenue from 2024 to 2025.
- This data is from Entrada Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: $0.00 | Q2 2022: $0.00 | Q3 2022: $0.00 | Q1 2023: $25.26 million | Q2 2023: $18.17 million | Q3 2023: $43.74 million | Q1 2024: $59.12 million | Q2 2024: $94.69 million | Q3 2024: $19.57 million | Q1 2025: $20.56 million | Q2 2025: $1.95 million | Q3 2025: $1.61 million.
- Over the full 3 years of available data (2023 to 2025), Entrada Therapeutics, Inc.'s Total Revenue has declined by 80.3%.
- Historical annual values: Fiscal year 2025: $25.42 million | Fiscal year 2024: $210.78 million | Fiscal year 2023: $129.01 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: